HEMOFILTRATION SYSTEMS, METHODS AND DEVICES FOR TREATMENT OF CHRONIC AND ACUTE DISEASES

• US 20080110830A1
• Filed: 11/05/2007
• Published: 05/15/2008
• Est. Priority Date: 03/24/2000
• Status: Active Grant

• Current Assignee: Immunocept Medical Products, LLC (LMF Acquisition Opportunities, Inc.)
• Original Assignee: Immunocept LLC
• Inventors: Matson, James R.
• Granted Patent: US 7,758,533 B2
• Time in Patent Office: Days
• US Class Current: 210/645
• CPC Class Codes: A61M 1/342 Adding solutions to the blood, e.g. substitution solutions for preventing coagulation A61M1/3672
• CPC Class Codes: A61M 1/3437 downstream of the filter, e.g. post-dilution with filtrate
• CPC Class Codes: A61M 1/3441 Substitution rate control as a function of the ultrafiltration rate
• CPC Class Codes: A61M 1/3455 Substitution fluids
• CPC Class Codes: A61M 1/3468 using treated filtrate as substitution fluid
• CPC Class Codes: A61M 1/3472 with treatment of the filtrate
• CPC Class Codes: A61M 1/3486 Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents

Abstract

A hemofiltration system and method to treat an Inflammatory Mediator Related Disease in a mammal, including chronic and acute diseases, include a hemofilter and an adsorptive device. The hemofilter removes ultrafiltrate from a blood stream extracted from the mammal to create a filtered blood stream and an ultrafiltrate stream. The adsorptive device may include one or more adsorbent materials and may be used to adsorb inflammatory mediators from the ultrafiltrate stream received from the hemofilter to create a post adsorption ultrafiltrate stream. The post adsorption ultrafiltrate stream may be selectively combined with the filtered blood stream and together with the filtered blood stream may be returned to the mammal.

Claims

1-39. -39. (canceled)

40. A hemofiltration system operable to treat an Inflammatory Mediator Related Disease in a mammal comprising:

a hemofilter operable to remove an ultrafiltrate from a blood stream extracted from the mammal and to create a filtered blood stream and an ultrafiltrate stream;

at least one therapeutic agent used in association with the hemofilter to treat the Inflammatory Mediator Related Disease; and

an adsorptive device containing at least one adsorbent material operable to receive the ultrafiltrate from the hemofilter and to remove an inflammatory mediator therefrom to create a post adsorption ultrafiltrate.

41. The system of claim 40, further comprising the adsorbent material selected from a group consisting of:

coated materials, uncoated materials, a matrix of rods, a matrix configured for convenient presentation of ultrafiltrate to adsorbent material, beads, particulates, and any combination thereof.

42. The system of claim 40, wherein the Inflammatory Mediator Related Disease further comprises an acute disease.

43. The system of claim 40, wherein the Inflammatory Mediator Related Disease further comprises a chronic disease.

49. The system of claim 40, further comprising the hemofilter having hollow fibers or parallel fibers.

50. The system of claim 40, wherein the hemofilter comprises a membrane and a jacket, further comprising:

the membrane including a material selected from a group consisting of;

polysulfone, polyacrylonitrile, polymethylmethacrylate, polyvinyl-alcohol, polyamide, polycarbonate, cellulose, cellulose derivatives, and any combination thereof; and

the jacket including polycarbonate.

51. The system of claim 40, further comprising the adsorbent material selected from a group consisting of silica, activated charcoal, nonionic or uncharged resins or polymers, ionic or charged resins or polymers, anion exchange resins or polymers, cation exchange resins or polymers, neutral exchange resins or polymers, immobilized polymyxin B, immobilized monoclonal antibodies, immobilized inflammatory mediator receptors, immobilized specific antagonists, cellulose, cellulose derivatives, synthetic materials, polysulfone, polyacrylonitrile, polymethylmethacrylate, polyvinyl-alcohol, polyamide, polycarbonate, polystyrene-derivative fibers, and any combination thereof.

52. The system of claim 40, wherein the ultrafiltrate stream comprises plasma water, electrolytes, and blood peptides and proteins.

53. The system of claim 40, further comprising tubing for use in combining the post adsorption ultrafiltrate stream with the filtered blood stream and returning the combined stream to the mammal.

56. The system of claim 40, further comprising the therapeutic agent selected from a group consisting of:

recombinant activated protein C, human protein C, proteolytic, amidolytic and esterolytic protein C, and any combination thereof.

57. The system of claim 40, further comprising the therapeutic agent selected from a group consisting of:

monoclonal antibodies, receptor antagonists, anti-tumor necrosis factor, interleukin 1 receptor antagonists, endotoxin antibodies, allopurinol, elastase inhibitors, prostaglandin inhibitors, and any combination thereof.

64. The system of claim 40, further comprising the hemofilter having a molecular weight exclusion limit equal to or greater than approximately 69,000 Daltons.

65. The system of claim 40, further comprising the hemofilter having a molecular weight exclusion limit up to 500,000 to 1,000,000 Daltons.

66. The system of claim 40, wherein the hemofilter comprises a 100 to 150 kiloDalton hemofilter.

44-48. -48. (canceled)

54-55. -55. (canceled)

58. A hemofiltration system for treating an Inflammatory Mediator Related Disease in a mammal comprising:

a hemofilter operable to receive blood from a mammal and to selectively remove an inflammatory mediator from the blood;

at least one therapeutic agent used in association with the hemofilter to treat the Inflammatory Mediator Related Disease; and

the therapeutic agent operable to reduce adverse effects of the inflammatory mediator.

59. The system of claim 58, further comprising the therapeutic agent selected from a group consisting of:

recombinant activated protein C, human protein C, proteolytic, amidolytic and esterolytic protein C, and any combination thereof.

60. The system of claim 58, further comprising the therapeutic agent selected from a group consisting of:

monoclonal antibodies, receptor antagonists, anti-tumor necrosis factor, interleukin 1 receptor antagonists, endotoxin antibodies, allopurinol, elastase inhibitors, prostaglandin inhibitors, and any combination thereof.

62. The system of claim 58, wherein the therapeutic agent is selected from the group consisting of a biological agent and a pharmaceutical agent.

63. The system of claim 58, wherein the hemofilter comprises a 100 to 150 kiloDalton hemofilter.

67. The system of claim 58, further comprising the hemofilter having a molecular weight exclusion limit equal to or greater than approximately 69,000 Daltons.

68. The system of claim 58, further comprising the hemofilter having a molecular weight exclusion limit up to 500,000 to 1,000,000 Daltons.

61. (canceled)